Alaina Doss

M. K. Doss is a clinical researcher working at the intersection of experimental psychopharmacology, cognitive neuroscience and psychiatric therapeutics. Their work encompasses controlled human studies in healthy volunteers and clinical populations, employing behavioural paradigms, cognitive testing and neuroimaging to examine how serotonergic compounds (notably psilocybin) and entactogens (notably MDMA) alter emotional processing, episodic memory processes and large-scale brain function. Doss has contributed to studies that track effects from the acute drug state through subacute windows of days to weeks after single high doses.

Key contributions include empirical investigations showing that a single high dose of psilocybin can produce measurable changes in emotion and brain function lasting up to one month, work demonstrating that MDMA impairs both encoding and retrieval of emotional recollections, and studies exploring how psilocybin and 2C‑B influence episodic familiarity. More clinically oriented work from Doss examines how psilocybin-assisted interventions relate to increases in cognitive and neural flexibility in people with major depressive disorder. Across these projects, Doss emphasises rigorous experimental design and mechanistic endpoints to inform both basic understanding and therapeutic development, while carefully delineating populations (healthy volunteers, depressive disorders, and other psychiatric groups) and cognitive domains affected by these compounds.